Imbruvica, Gazyva combo meets in first-line CLL

AbbVie Inc. (NYSE:ABBV) said Imbruvica ibrutinib plus Gazyva obinutuzumab met the primary endpoint of improving progression-free survival (PFS) in the Phase III iLLUMINATE (PCYC-1130) trial to treat previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).

The open-label trial enrolled 212 patients to receive Imbruvica plus Gazyva or chlorambucil plus Gazyva. PFS was assessed by an independent review committee...